iShares MSCI South Korea ETF vs Heron Therapeutics Inc — how do they compare? iShares MSCI South Korea ETF trades at $166.06, while Heron Therapeutics Inc trades at $0.45 (market cap $84.50M). The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EWY | HRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $2.02 |
52-Week Low | $70.65 | $0.39 |
Market Cap | — | $84.50M |
Enterprise Value | — | $182.40M |
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, is trading at $166.48, down 5.93% amid significant volatility in South Korean equities. Technical indicators show a bearish trend with strong selling pressure, while the underlying Kospi Index has experienced sharp declines from recent highs. The ETF remains heavily concentrated in Samsung and SK Hynix, making it highly sensitive to semiconductor and AI market dynamics.
The outlook remains challenging with ongoing volatility in chip stocks and foreign investor selling. While long-term AI demand provides potential upside, current market conditions suggest continued pressure. Key risks include single-stock concentration and global tech sector volatility, requiring careful risk management for investors.
HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.
The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.
Trailing returns across standard periods
Latest headlines on both assets
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →